Anti-uPA (human, urokinase plasminogen activator)
Mouse monoclonal antibody
Cat.No. MON U-6
Preparation: Protein-A purified
Content: Available in 200 µL and 1 mL
Concentration: 1 mg/mL
Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
Storage: In the dark at 4-8ºC
Urokinase plasminogen activator (uPA) is a serine protease. It converts the abundant proenzyme plasminogen to active plasmin and plays a key role in cancer invasion and a variety of tissue remodelling processes such as wound healing, mammary gland involution and placental development (1-3). Elevated levels of uPA are associated with poor prognosis in many types of cancer (2-5).
Native human uPA
MON U-6 is specific for human uPA. No reaction with human tissue plasminogen activator (tPA) is seen when tested by ELISA, immunoblotting and enzyme inhibition. No reaction with any other human plasma proteins is seen when tested by immunoblotting.
MON U-6 binds to the A-chain of uPA (6)
MON U-6 binds single and two-chain uPA, uPA/PAI-1 complex and uPA/uPAR complex. A reaction is seen with the amino terminal fragment (ATF) but not with LMW uPA. MON U-6 reacts with reduced and non-reduced uPA in Western blotting. It inhibits the enzymatic activity of uPA in the fibrin plate assay. MON U-6 can be used on frozen sections in immunohistochemistry applications (7).
| Method | Usability | Dilution guideline | References |
| ELISA | Yes | 5,8,9 | |
| Immunoblotting | Yes | ||
| Immunohistochemistry | Yes | 7 |
1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266.
2. Andreasen PA, Kjøller L, Christensen L, Duffey MJ (1997) The urokinase plasminogen activator system in cancer metastasis. Int J Cancer 2:1-22.
3. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J (2005) Plasminogen activation and cancer. Thromb Haem 93:676-681.
4. Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk acording to urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). Cancae Res 62:4617-22.
5. Kaltoft K, Nielsen LS, Zeuthen J, Danø K (1982) Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci USA 79:3720-3723.
6. Nielsen LS, Grøndahl-Hansen J, Andreasen PA, Skriver L, Zeuthen J, Danø K (1986) Enzyme linked immunosorbent assay for human urokinase type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay 7:209-228.
7. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521.
8. Pedersen AN, Christensen IJ, Stephens RW, Briand P, Mouridsen HT, Danø K, Brünner N (2000) The complex between urokinase and its type-1 inhibitor in primary breast cancer: Relation to survival Cancer Res 60: 6927-6934.
9. Nielsen BS, Sehested M, Dunn S, Rank F, Timshel S, Rygaard J, Johnsen M, Danø K (2001) Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab Invest 81:1485-1501.
Related Articles
Antibody MSDS
April 23 2008
Related News
New tools for cancer research: Plasminogen Activation System anti-bodies
May 05 2008
